Longer interval between mRNA COVID-19 jabs improves immune response

Embargoed until: Publicly released: 2021-12-06 13:00

International

Pfizer-BioNTech_COVID-19_vaccine_(2020)_C By U.S. Secretary of Defense, CC BY 2.0

Longer mRNA vaccine dosing intervals improved patients' immune response against COVID-19, according to a small Canadian study, and the authors say their data suggest extending dosing intervals may be particularly advantageous against the Delta variant. When vaccine supplies are limited, delaying second doses may be the best strategy to ensure the highest possible proportion of the population has some immunity, they suggest, although they add that this would be a risky approach among vulnerable groups, or when COVID-19 case numbers are very high.

Media release

From: JAMA

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals

This study investigated the immunogenicity of extended mRNA vaccine dosing intervals.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page

Journal/
conference: JAMA

Research:Paper

Organisation/s: University of British Columbia, Canada

Funder: This study was supported by funding from the government of Canada, through the COVID-19 Immunity Task Force.

Media Contact/s

Contact details are only visible to registered journalists.